The RAS proteins, KRAS4A, KRAS4B, HRAS, and NRAS control diverse cellular processes, and gain-of-function mutations in RAS genes are found in ~25% of cancers in humans, with KRAS mutations accounting for up to 85% of RAS mutations across cancers. While KRAS G12C has been successfully targeted by approved drugs sotorasib and adagrasib and numerous candidates [...]
6 minute read
Jul. 7, 2023
Why is the pan-KRAS inhibitor, BI-2493, a big deal?
BI-2493
oral reversible pan-KRAS inhibitor oral activity in xenograft models (10-90 mpk BID) from prior covalent KRAS G12C inhibitor Nature, May 31, 2023 Boehringer Ingelheim, Vienna, AT
Loading...
